Topical cetirizine and oral vitamin D: a valid treatment for hypotrichosis caused by ectodermal dysplasia

Rossi, Alfredo; Miraglia, Emanuele; Fortuna, Maria Caterina; Calvieri, Stefano; Giustini, Sandra

doi:10.1111/jdv.13864

Cited by 6 publications

(7 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The vellus hair replacement by terminal hair was noticed in this report. Furthermore, after 6 months of treatment, the density of hair on the scalp increased in all patients from clinical and trichoscopic points of view (8). Also, recently published a research article in the journal of cosmetic dermatology which indicated a potential role of cetirizine 1% in treating AGA (18).…”

Section: Discussionmentioning

confidence: 93%

“…Cetirizine hydrochloride belongs to a family of medicines called antihistamine which has varied medical uses and is commonly used to relieve allergy symptoms such as watery eyes, runny nose, sneezing, hives, and itching. In addition, it has been demonstrated that cetirizine inhibits release of prostaglandin D2 and stimulates the release of prostaglandin E2 (6,8). Furthermore, it has antiinflammatory properties which can be useful because perifollicular micro-inflammation of the scalp is one of deteriorating factors in AGA (9,1).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of Cetirizine 1% Versus Minoxidil 5% Topical Solution in the Treatment of Male Alopecia: A Randomized, Single-blind Controlled Study

et al. 2021

View full text Add to dashboard Cite

Purpose: Prostaglandins play a pivotal role in modulating hair growth cycle. Prostaglandin F2α and prostaglandin E have stimulating and prostaglandin D has inhibitory effects on hair follicle. Cetirizine inhibits release of prostaglandin D2 and stimulates the release of prostaglandin E2. In the present study, the efficacy and safety of twice daily application of topical cetirizine 1% versus minoxidil 5% solutions for 16 weeks were compared in male androgenetic alopecia (AGA). Methods: Forty men, aged 18 to 49 years, ‎were randomly divided into two equal groups to apply either cetirizine 1% or minoxidil 5% solutions. The study was divided into two phases, a 16-week treatment phase either with cetirizine or minoxidil (anagen phase), followed by an 8-week ‎ drug-free (telogen phase) with a follow-up when patients used placebo. Efficacy outcomes included the change in total hair density, vellus and terminal hair density, hair diameter and the percentage of hair in anagen and telogen phases from baseline in 16 and 24 weeks. Results: After 16 weeks, we observed a significant increase in total and vellus hair density in both minoxidil and cetirizine groups, but the improvement was much higher in the minoxidil group. The percentage of hair in the anagen phase also increased in both groups after 16 weeks of treatment, but then diminished after 8 weeks of placebo consumption. No significant adverse reactions associated with the administration of cetirizine solution were reported. Conclusion: Cetirizine 1% solution was effective in hair growth without any complications for treatment of male AGA.

show abstract

Section: Discussionmentioning

confidence: 93%

Section: Introductionmentioning

confidence: 99%

Efficacy of Cetirizine 1% Versus Minoxidil 5% Topical Solution in the Treatment of Male Alopecia: A Randomized, Single-blind Controlled Study

et al. 2021

View full text Add to dashboard Cite

show abstract

“…), and black dots (B.D). Table (2) Photographic examples of clinical and dermoscopic responses in patients are demonstrated in Figures 3-4.…”

Section: Resultsmentioning

confidence: 99%

Efficacy of Topical Cetirizine 1% in Treatment of Androgenic Alopecia: Clinical and Dermoscopic Evaluation

Galal

Mahmoud

Ahmed

2023

Preprint

View full text Add to dashboard Cite

Background: Androgenetic alopecia (AGA) is a form of non-scarring scalp hair loss that affects more than 50% of males. Prostaglandins would have an important role in hair growth and their action is variable according to their class. Based on these and the scarce studies that suggest the effectiveness of cetirizine on AGA we carried out this study. Aim of Work: Dermoscopic evaluation of the efficacy of topical cetirizine 1 % in male patients with androgenetic alopecia. Materials and methods: A prospective study was carried out on 50 Egyptian male patients treated with topical cetirizine 1% formula once daily. The clinical and dermoscopic examination was done before, during, and after treatment to evaluate the response. Results: There was a significant increase in the number of terminal hairs, a decrease in the number of vellus hair, and hair diameter diversity after treatment. There was mild to good photographic improvement. Conclusion: Topical cetirizine 1 % had a promising effect in the treatment of AGA in men after 4 months of treatment. It also is having an excellent safety profile which could be an excellent option in the near future for the patients.

show abstract

“…Since the increase in hair density was significant in both groups, it will be hard to know if cetirizine had a role in it. However, a short report by Rossi et al in patients with congenital hypotrichosis caused by ectodermal dysplasia [ 24 ] and a case report of a 70-year-old woman with chemotherapy-induced alopecia [ 25 ] showed positive effect of topical cetirizine on hair density.…”

Section: Discussionmentioning

confidence: 99%

Comparison between topical cetirizine with minoxidil versus topical placebo with minoxidil in female androgenetic alopecia: a randomized, double-blind, placebo-controlled study

et al. 2022

View full text Add to dashboard Cite

Androgenetic alopecia (AGA) is the most common cause of hair loss in both genders with a higher psychological impact on females. Currently, topical minoxidil is the only FDA-approved treatment for female AGA and it needs life-long application and causes side effects. Cetirizine is an antihistamine that may be effective in hair loss treatment. This study aimed to compare the efficacy and safety of topical cetirizine with minoxidil (group 1) versus topical minoxidil with placebo (group 2) in female patients with AGA. This was a double-blind, randomized, controlled, parallel study conducted at Dermatology Clinic, Cairo University Teaching Hospital (Kasr- Al- Ainy), Egypt. Sixty-six patients with female AGA, aged 20–50 years, Sinclair (II–IV), were randomly assigned to one of the 2 groups for 24 weeks. The trichoscopic parameters, patients’ self-assessment, side effects and global photographic assessment were evaluated. There was a statistically significant change from baseline in frontal and vertex terminal and vellus hair density (P < 0.0005) with a significant increase in vertex hair shaft thickness and average number of hairs per follicular unit in group 1 (P < 0.05). Patients reported significantly better scores in patient self-assessment in group 1 (P < 0.05). Side effects were not significantly different between groups (P > 0.05). Topical cetirizine increases hair shaft thickness and results in a higher clinical improvement from patients’ perspective with a good safety profile (NCT04481412, study start date: July 2020).

show abstract

Topical cetirizine and oral vitamin D: a valid treatment for hypotrichosis caused by ectodermal dysplasia

Abstract: We propose a combination of topical cetirizine and oral vitamin D as a rational treatment of choice in congenital hypotrichosis caused by ectodermal dysplasia.

Cited by 6 publications

References 21 publications

Efficacy of Cetirizine 1% Versus Minoxidil 5% Topical Solution in the Treatment of Male Alopecia: A Randomized, Single-blind Controlled Study

Efficacy of Cetirizine 1% Versus Minoxidil 5% Topical Solution in the Treatment of Male Alopecia: A Randomized, Single-blind Controlled Study

Efficacy of Topical Cetirizine 1% in Treatment of Androgenic Alopecia: Clinical and Dermoscopic Evaluation

Comparison between topical cetirizine with minoxidil versus topical placebo with minoxidil in female androgenetic alopecia: a randomized, double-blind, placebo-controlled study

Contact Info

Product

Resources

About